Lv11
10 积分 2022-11-11 加入
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
2小时前
待确认
Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma
6个月前
已完结
Malignant carotid body tumors: What we know, what we do, and what we need to achieve. A systematic review of the literature
6个月前
已完结
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy
7个月前
已完结
Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer
7个月前
已完结
A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
7个月前
已完结
An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC
7个月前
已完结
Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
8个月前
已完结
皖公网安备34019202002308
